DURATION-1: Exenatide Once Weekly Produces Sustained Glycemic Control andWeight Loss Over 52 Weeks JOHNB. B USE,MD, PHD1 DANIEL J. D RUCKER ,MD2 KRISTIN L. T AYLOR ,PHD3 TERRIKIM,MS3 BRANDON WALSH,PHD3 HAOHU,MS3KENWILHELM ,MD3 MICHAEL TRAUTMANN ,MD4 LARRY Z. S HEN,PHD3 LISAE. P ORTER ,MD3 FOR THE DURATION-1 S TUDY GROUP* OBJECTIVE — In the Diabetes Therapy Utilization: Researching Changes in A1C, Weight and Other Factors Through Intervention with Exenatide Once Weekly (DURATION-1) study,the safety and efﬁcacy of 30 weeks of treatment with the glucagon-like peptide-1 receptor agonistexenatide once weekly (exenatide QW; 2 mg) was compared with exenatide BID in 295 patientswith type 2 diabetes. We now report the safety and efﬁcacy of exenatide QW in 1) patients who continued treatment for an additional 22 weeks (52 weeks total) and 2) patients who switched from exenatide BID to exenatide QW after 30 weeks. RESEARCH DESIGN AND METHODS — In this randomized, multicenter, compara-